Medivir AB (MVRBF) Release: SVR12 Results From A Phase 2a Study Evaluating Simeprevir And Daclatasvir In Hepatitis C Patients Of Genotype 1 Have Been Presented
3/5/2014 9:10:43 AM
Stockholm, Sweden — Medivir AB (OMX: MVIR) today announced that study results
from a phase IIa trial evaluating simeprevir, a once-daily protease inhibitor
jointly developed by Janssen R&D Ireland and Medivir AB, in combination with
daclatasvir, an investigational once-daily NS5A inhibitor developed by Bristol
-Myers Squibb (NYSE: BMY), with and without ribavirin, in patients with
hepatitis C (HCV) genotype 1 infection, have been presented at the 21th
Conference on Retroviruses and Opportunistic Infections (CROI) on March 4th in
Boston, USA. The study was conducted by Bristol-Myers Squibb.
Help employers find you! Check out all the jobs and post your resume.
comments powered by